FDA Clears Inovio’s DNA Immunotherapy for Adult Recurrent Respiratory Papillomatosis
The FDA has approved Voceryq, Inovio Pharmaceuticals’ DNA-based immunotherapy for adults with recurrent respiratory papillomatosis, or RRP, a rare HPV-driven disease that can force patients back to the operating room again and again. The decision gives clinicians a second FDA-approved drug option in an indication long dominated by surgery, and it brings a new mechanism to a disorder that has remained stubbornly procedural for years.
RRP arises from infection with human papillomavirus type 6 or 11. The disease produces papillomas in the respiratory tract, where even benign growths can cause hoarseness, impaired speech, airway obstruction, and in severe cases life-threatening compromise. Surgical debulking has been the standard approach, but it does not clear the underlying viral driver, so the tumors commonly recur. For many patients, the practical burden is relentless: repeated anesthesia, repeated airway instrumentation, repeated recovery, and repeated risk to the vocal cords and surrounding tissue.
That is the gap Inovio is trying to fill. Voceryq is built from two plasmids, one encoding HPV antigens and the other encoding interleukin-12, or IL-12, a cytokine that amplifies immune activation. The goal is not to remove papillomas directly, but to retrain the immune system to recognize and attack HPV-6 and HPV-11–related proteins. In immunologic terms, the therapy aims to convert a chronic, evasive infection into a target the host can better see.
The regimen is compact: one dose every three weeks for four doses. The FDA approved the therapy for adult patients as a way to reduce the frequency of surgeries needed to manage the condition, and it also approved a proprietary Inovio device used to administer the medicine. The product will reach market at a list price of $115,000 per dose, or $460,000 for the full course.
Phase 1/2 Data That Supported Accelerated Approval
The regulatory decision rests on an open-label Phase 1/2 study in 32 adults with RRP. Among the 32 enrolled participants, 26 had required three or more surgeries in the 12 months before receiving the investigational treatment. In that subgroup, seven achieved a complete response, defined as needing no surgery during 12 months of follow-up. Overall, the study showed a statistically significant reduction in surgical interventions compared with the year before treatment.
Those data do not describe a cure, and they do not erase the need for procedures. They do show a meaningful shift in disease control for a condition defined by recurrent recurrence. When a therapy reduces the number of surgeries in a disorder where surgery is the default state of care, the clinical meaning is immediate: fewer airway procedures, fewer interruptions to daily life, and less cumulative trauma to the larynx and respiratory tract.
The FDA granted accelerated approval, which means Inovio must run a confirmatory study to verify clinical benefit. That requirement matters because the approval is anchored in a relatively small, single-arm dataset. The benefit signal is compelling enough to open the door, but it still needs to survive the harder test of a larger, better-controlled trial.
A Second Drug Enters a Narrow RRP Market
Voceryq is entering a market that already has one approved competitor. Last year, Precigen’s Papzimeos became the first FDA-approved drug for recurrent respiratory papillomatosis. The two products share the same list price, and both still require surgery before treatment begins.
Their labels differ after that point. Precigen’s label calls for additional surgeries before the third and fourth doses if papillomas remain visible. Inovio says Voceryq does not require surgeries before doses three and four, a distinction company executives are presenting as a competitive advantage. Jacqueline Shea, Inovio’s chief executive, said the company designed the trial that way because every surgery matters to patients.
The comparison is clinically meaningful because RRP is not just a diagnosis; it is a chronic airway management problem. Each extra operation can scar tissue, affect voice quality, and consume medical resources. A therapy that reduces the number of downstream procedures may matter as much as the headline response rate, particularly in a disease where the therapeutic burden has traditionally been shared between the patient and the operating room.
Why the Biology Fits the Clinical Need
RRP is driven by persistent viral infection rather than by an oncogenic process in the usual sense, yet the lesions behave like recurring tumors in the airway. That makes immunotherapy a biologically plausible strategy. By combining antigen expression with IL-12–driven immune stimulation, Voceryq is designed to increase recognition of HPV-derived targets and support a more durable local and systemic response.
The logic is straightforward: surgery removes what is already visible, while immunotherapy attempts to slow the return of what cannot be seen. In a disease that repeatedly repopulates the airway, the latter approach targets the source of the relapse rather than the relapse itself. The clinical challenge is whether immune activation will stay strong enough over time to keep the papillomas from rebuilding the same pattern of obstruction and resection.
Inovio estimates, based on insurance claims data, that the U.S. market for adult RRP includes about 25,000 patients. The company says its label covers adult patients broadly, while still requiring a history of prior surgeries to determine eligibility. Executives also said many patients are seeking alternatives to surgery, yet only a small fraction have received immunotherapy so far. That leaves room for uptake if clinicians see practical value in the new option and if payers accept the economics of a high-cost rare-disease product.
Launch Timing, Funding, and the Next Test
Inovio expects Voceryq to become available within 60 days. The company said it had $36.7 million in cash at the end of June and raised another $20 million in July. Shea said the company is funded for the launch and expects cash to last into the first quarter of 2027, though further financing will be needed and management is evaluating options.
The launch will test more than commercial demand. It will test whether a DNA-based platform can establish a foothold in a rare airway disease where the standard of care has been procedural for decades and where a rival product already has first-mover advantage. It will also test whether patients and surgeons view fewer future operations as enough of an outcome to justify another expensive biologic-style intervention.
For now, Voceryq arrives with a clear regulatory milestone and a narrower evidence base than a traditional approval would require. The confirmatory trial will need to answer the question that matters most in the clinic: whether the reduction in surgery can be reproduced, sustained, and translated into durable control of a disease that has long returned after every trip to the OR.